NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Small Cell Lung Cancer
Prostate Cancer
Lung Neoplasms
Urothelial Carcinoma
Urothelial Cancer

Interventions: Drug: EP0057
Drug: olaparib

First Posted Date: 2016-05-12

Last Posted Date: 2025-02-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT02769962

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Phase 2

Completed

Conditions: Locally Advanced Papillary Renal Cell Carcinoma
Metastatic Papillary Renal Cell Carcinoma
Type 1 Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7
Unresectable Renal Cell Carcinoma
Type 2 Papillary Renal Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Cabozantinib S-malate
Drug: Sunitinib Malate
Drug: Crizotinib
Drug: Savolitinib

First Posted Date: 2016-05-04

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT02761057

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 592 locations

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase 2

Completed

Conditions: Lung Adenocarcinoma
Lung Neoplasms

Interventions: Drug: osimertinib
Other: Local Ablative Therapy (LAT)

First Posted Date: 2016-05-03

Last Posted Date: 2024-06-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT02759835

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Completed

Conditions: Chronic Graft-Versus-Host Disease
Chronic Graft vs Host Disease

Interventions: Drug: Baricitinib

First Posted Date: 2016-05-03

Last Posted Date: 2024-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT02759731

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis

Phase 2

Completed

Conditions: Acute Pancreatitis

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Placebo Administration
Other: Questionnaire Administration
Drug: Simvastatin

First Posted Date: 2016-04-19

Last Posted Date: 2022-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT02743364

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

Early Life Exposures in Agriculture

Completed

Conditions: Lymphoma
Brain Cancer
Testicular Cancer
Leukemia

First Posted Date: 2016-04-19

Last Posted Date: 2020-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60000

Registration Number: NCT02743481

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test

Completed

Conditions: Cancers

First Posted Date: 2016-04-12

Last Posted Date: 2021-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT02734303

Locations: 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Veliparib + VX-970 + Cisplatin

First Posted Date: 2016-03-31

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT02723864

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Phase 1

Completed

Conditions: Gliosarcoma
Astrocytoma, Grade IV
Giant Cell Glioblastoma
Glioblastoma Multiforme

Interventions: Radiation: Radiation

First Posted Date: 2016-03-16

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02709226

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Conditions: Cancer

First Posted Date: 2016-03-11

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 900

Registration Number: NCT02706652

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy